Glecirasib

SKU: orb1944488

Description

Glecirasib (JAB-21822) is an oral KRAS G12C inhibitor that selectively targets and inactivates the mutant protein, blocking downstream oncogenic signaling. Preclinical studies in animal models demonstrate its antitumor efficacy and favorable safety profile, supporting its investigation in cancers driven by this mutation.

Research Area

Pharmacology & Drug Discovery, Signal Transduction

Key Properties

• CAS Number: 2657613-87-9
• MW: 640.03
• Purity: >99.99% (May vary between batches)
• Formula: C₃₁H₂₆ClF₄N₇O₂
• SMILES: N#CC=1C(=O)N(C=2N=C(C(Cl)=CC2C1N3CCN(C(=O)C=C)CC3)C=4C(F)=C(F)C(F)=C(F)C4N)C=5C(=NC=CC5C)C(C)C
• Target: Ras,Kras

Bioactivity

• Target IC50:
  KRas (G12C):1.6 nM
• In Vivo:
  Methods: Glecirasib (10 mg/kg, oral, once a day, 3 weeks) was used to treat NCI-H1373 xenograft mice, and the tumor growth and body weight growth in the mice were observed. Results: Glecirasib inhibited tumor growth in the NCI-H1373 xenograft mouse model and had no significant effect on the body weight of the mice, indicating high safety. [1-3]
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

KRAS G12C inhibitor 36, JAB21822, JAB-21822, JAB-21000, JAB21000

Compound Identifiers

PubChem CID

157827766